Difference between revisions of "PCSEAT"
(→Expression) |
(→Expression) |
||
| Line 19: | Line 19: | ||
PCSEAT promotes cell proliferation by affecting miR-143-3p- and miR-24-2-5p-mediated regulation of EZH2, suggesting that PCSEAT and EZH2 competitively 'sponge' miR-143-3p and miR-24-2-5p.<ref name="ref2" /> | PCSEAT promotes cell proliferation by affecting miR-143-3p- and miR-24-2-5p-mediated regulation of EZH2, suggesting that PCSEAT and EZH2 competitively 'sponge' miR-143-3p and miR-24-2-5p.<ref name="ref2" /> | ||
===Expression=== | ===Expression=== | ||
| − | [[File: PCSEAT. | + | [[File: PCSEAT.png|thumb|300px| PCSEAT regulates EZH2 through miR-143-3p and 31 miR-24-2-5p.<ref name="ref2"/>]] |
The expression levels of PCSEAT were significantly upregulated in human prostate cancer tissues.<ref name="ref1" /> | The expression levels of PCSEAT were significantly upregulated in human prostate cancer tissues.<ref name="ref1" /> | ||
Bioactive PCSEAT is incorporated into exosomes and transmitted to adjacent cells, thus promoting cell proliferation and motility.<ref name="ref2" /> | Bioactive PCSEAT is incorporated into exosomes and transmitted to adjacent cells, thus promoting cell proliferation and motility.<ref name="ref2" /> | ||
Revision as of 02:20, 19 February 2021
PCSEAT promoting cell proliferation and motility and a potential oncogene in PCa cells via mediating EZH2 activity.[1][2]
Contents
Annotated Information
Name
Approved symbol:PCSEAT
Approved name:prostate cancer expressed EZH2 associated transcript
HGNC ID HGNC:54485
Alias symbol:PRCAT38
RefSeq ID:NR_164474
Characteristics
PCSEAT in human prostate cancer tissues.[2]
Function
PCSEAT is specifically overexpressed in PCa patients and a potential oncogene in PCa cells via mediating EZH2 activity.[1]
Regulation
PCSEAT promotes cell proliferation by affecting miR-143-3p- and miR-24-2-5p-mediated regulation of EZH2, suggesting that PCSEAT and EZH2 competitively 'sponge' miR-143-3p and miR-24-2-5p.[1]
Expression
The expression levels of PCSEAT were significantly upregulated in human prostate cancer tissues.[2] Bioactive PCSEAT is incorporated into exosomes and transmitted to adjacent cells, thus promoting cell proliferation and motility.[1]
Diseases
Prostate cancer[2]
Labs working on this lncRNA
- Faculty of Biological Sciences, Department of Genetics, Tarbiat Modares University, Tehran, Iran.[2]
- Urology and Nephrology Research Centre, Labbafi-Nejad Medical Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran.[2]
- Laboratory for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, 200444, China; CAS Key Laboratory of Bio-medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China.[1]
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.[1]
- CAS Key Laboratory of Bio-medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China.[1]
- Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China.[1]
- Medical College, Guizhou University, Guiyang, 550025, China.[1]
- CAS Key Laboratory of Bio-medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, 215163, China; Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China; Medical College, Guizhou University, Guiyang, 550025, China. Electronic address: gaos@sibet.ac.cn.[1]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Yang X, Wang L, Li R, Zhao Y, Gu Y, Liu S, Cheng T, Huang K, Yuan Y, Song D, Gao S. The long non-coding RNA PCSEAT exhibits an oncogenic property in prostate cancer and functions as a competing endogenous RNA that associates with EZH2. Biochem Biophys Res Commun. 2018 Jul 12;502(2):262-268. doi:10.1016/j.bbrc.2018.05.157. Epub 2018 May 26.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Bayat H, Narouie B, Ziaee SM, Mowla SJ. Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer. Prostate. 2018 Aug;78(11):812-818. doi: 10.1002/pros.23538. Epub 2018 Apr 19.
